Antipsychotic Treatment Within a Naturalistic Trial—How Are We Treating Schizophrenia Patients in the “Real-World”?
- 20 December 2012
- book chapter
- Published by Springer Nature
- p. 137-156
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009Schizophrenia Research, 2012
- Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in JapanClinicoEconomics and Outcomes Research, 2012
- Amisulpride Augmentation of Clozapine in Refractory SchizophreniaThe Journal of Neuropsychiatry and Clinical Neurosciences, 2011
- Amisulpride Improved Debilitating Clozapine-Induced SialorrheaAmerican Journal of Therapeutics, 2011
- Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001–2008)International Journal of Neuropsychopharmacology, 2011
- Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophreniaSchizophrenia Research, 2009
- Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug UsePLOS ONE, 2008
- Use of combinations of antipsychotics: McLean Hospital inpatients, 2002Human Psychopharmacology: Clinical and Experimental, 2005
- Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of SchizophreniaNeuropsychopharmacology, 2003
- Role of Antipsychotic Polypharmacotherapy in the Treatment of SchizophreniaCNS Drugs, 1999